MARY HUNT: Open Payments
NPI 1457816688 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$428 in 19 payments from 11 companies in 2025. Trend: 2023 $505 · 2024 $117 · 2025 $428
Food & beverage: $428
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $85 |
| ABBVIE INC. | 2 | $56 |
| Madrigal Pharmaceuticals | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Baxter Healthcare | 1 | $32 |
| Alexion Pharmaceuticals, Inc. | 2 | $32 |
| La Jolla Pharmaceutical Company | 1 | $29 |
| Eisai Inc. | 1 | $27 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $24 |
Products named: XIFAXAN, REZDIFFRA, LIVTENCITY, PERCLOT, ULTOMIRIS, GIAPREZA, Lenvima, Exparel.
Industry payments across TX — which companies pay providers there.
